Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

A therapeutic composition for topical treatment of ocular hypertension or glaucoma, containing a prostaglandin PGD in an amount sufficient to reduce intraocular pressure without causing substantial ocular irritation and an ophthalmologically compatible vehicle, in which the alpha chain of the prostaglandin comprises a chain of 6 to 10 carbon atoms, which is either

• (a) saturated or
• (b) unsaturated having one or more non-cumulated double bonds, or a triple bond,
• the alpha chain being
• (c) unsubstituted or
• (d) substituted with one or more substituents selected from the group of alkyl groups, alicyclic rings, aromatic rings or heteroaromatic rings,
• and in which the omega chain of the prostaglandin has the formula
• C.sub.13 --B--C.sub.14 --D.sub.15-24 --R.sub.2
• wherein
• C is a carbon atom (the number according to standard prostaglandin nomenclature being indicated by the subscript);
• B is a single bond, a double bond, or a triple bond;
• D represents a sub-chain of 1-10 carbon atoms and 1-2 heteroatoms selected from the group that consists of O, N, and S, with substituents on each sub-chain atom that are selected from the group consisting of a hydrogen atom, an alkyl group, an oxo group and a hydroxyl group, and
• R.sub.2 is an aromatic ring structure which is unsubstituted or has at least one substituent selected from the group consisting of
• C.sub.1 -C.sub.5 alkyl groups,
• C.sub.1 -C.sub.4 alkoxy groups,
• trifluoromethyl groups,
• C.sub.1 -C.sub.3 aliphatic acylamino groups,
• nitro groups,
• halogen atoms,
• a phenyl group.